The sFlt-1/PlGF ratio has the potential to be implemented in clinical practice to guide appropriate intensity of patient management with respect to hospitalization and therapeutic decisions in a clinically relevant proportion of pregnant women with signs and symptoms of preeclampsia, eclampsia or HELLP syndrome. This evidence concerns the gene PGF and preeclampsia.